Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.
In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery.
The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -2.30 Decreased by -16.16% | -1.50 Decreased by -53.33% |
| Feb 13, 24 | -0.05 Increased by +98.65% | -2.17 Increased by +97.70% |
| Nov 7, 23 | -2.88 Increased by +4.95% | -2.38 Decreased by -21.01% |
| Sep 5, 23 | -2.16 Decreased by -47.95% | -2.59 Increased by +16.60% |
| Apr 27, 23 | -1.98 Increased by +10.41% | -2.66 Increased by +25.56% |
| Feb 16, 23 | -3.70 Decreased by -97.86% | -2.56 Decreased by -44.53% |
| Nov 2, 22 | -3.03 Decreased by -106.12% | -2.49 Decreased by -21.69% |
| Aug 10, 22 | -1.46 Increased by +41.60% | -2.13 Increased by +31.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 48.03 M Increased by +214.15% | -162.22 M Increased by +3.98% | Decreased by -337.73% Increased by +69.44% |
| Jun 30, 23 | 47.39 M Increased by +669.37% | -121.43 M Decreased by -49.33% | Decreased by -256.23% Increased by +80.59% |
| Mar 31, 23 | 33.59 M Increased by +391.93% | -110.91 M Increased by +11.62% | Decreased by -330.21% Increased by +82.03% |
| Dec 31, 22 | 22.90 M Increased by +367.55% | -207.42 M Decreased by -95.56% | Decreased by -905.91% Increased by +58.17% |
| Sep 30, 22 | 15.29 M Increased by +1.27 K% | -168.96 M Decreased by -110.28% | Decreased by -1.11 K% Increased by +84.69% |
| Jun 30, 22 | 6.16 M Increased by +502.74% | -81.32 M Increased by +39.48% | Decreased by -1.32 K% Increased by +89.96% |
| Mar 31, 22 | 6.83 M Increased by +815.28% | -125.50 M Decreased by -99.86% | Decreased by -1.84 K% Increased by +78.16% |
| Dec 31, 21 | 4.90 M Increased by +815.33% | -106.06 M Increased by +23.68% | Decreased by -2.17 K% Increased by +91.66% |